Therapeutic Status and Available Strategies in Pancreatic Ductal Adenocarcinoma
One of the most severe and devastating cancer is pancreatic cancer. Pancreatic ductal adenocarcinoma (PDAC) is one of the major pancreatic exocrine cancer with a poor prognosis and growing prevalence. It is the most deadly disease, with an overall five-year survival rate of 6% to 10%. According to v...
Main Authors: | Gitika Thakur, Raj Kumar, Saet-Byul Kim, Sang-Yeob Lee, Sung-Lim Lee, Gyu-Jin Rho |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-02-01
|
Series: | Biomedicines |
Subjects: | |
Online Access: | https://www.mdpi.com/2227-9059/9/2/178 |
Similar Items
-
The Latest Advancement in Pancreatic Ductal Adenocarcinoma Therapy: A Review Article for the Latest Guidelines and Novel Therapies
by: Marwa Elsayed, et al.
Published: (2021-04-01) -
Clinically impactful metabolic subtypes of pancreatic ductal adenocarcinoma (PDAC)
by: Jannat Pervin, et al.
Published: (2023-10-01) -
Development and validation of a cancer stem cell-related signature for prognostic prediction in pancreatic ductal adenocarcinoma
by: Zengyu Feng, et al.
Published: (2020-09-01) -
The challenge of drug resistance in pancreatic ductal adenocarcinoma: a current overview
by: Francisco Quiñonero, et al.
Published: (2019-12-01) -
Targeting autophagy in pancreatic cancer: The cancer stem cell perspective
by: Dimitrios Troumpoukis, et al.
Published: (2022-11-01)